
- The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68 on day volume of 648.08 thousand shares, closed regular trading session at $92.90. The company shares traded at $94.84, up 2.09 percent in the after-hours trading session.
- Ligand Pharmaceuticals (NASDAQ:LGND) announced that the Janssen Biotech (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Ligand shares traded as high as 2.66 percent, in a range of $99.83 to $104.29 on day volume of 64.59 thousand shares, closed regular trading session at $103.34.